2020
Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium
Polimanti R, Walters RK, Johnson EC, McClintick JN, Adkins AE, Adkins DE, Bacanu SA, Bierut LJ, Bigdeli TB, Brown S, Bucholz KK, Copeland WE, Costello EJ, Degenhardt L, Farrer LA, Foroud TM, Fox L, Goate AM, Grucza R, Hack LM, Hancock DB, Hartz SM, Heath AC, Hewitt JK, Hopfer CJ, Johnson EO, Kendler KS, Kranzler HR, Krauter K, Lai D, Madden PAF, Martin NG, Maes HH, Nelson EC, Peterson RE, Porjesz B, Riley BP, Saccone N, Stallings M, Wall TL, Webb BT, Wetherill L, Edenberg H, Agrawal A, Gelernter J. Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. Molecular Psychiatry 2020, 25: 1673-1687. PMID: 32099098, PMCID: PMC7392789, DOI: 10.1038/s41380-020-0677-9.Peer-Reviewed Original Research
2009
A pilot multivariate parallel ICA study to investigate differential linkage between neural networks and genetic profiles in schizophrenia
Meda SA, Jagannathan K, Gelernter J, Calhoun VD, Liu J, Stevens MC, Pearlson GD. A pilot multivariate parallel ICA study to investigate differential linkage between neural networks and genetic profiles in schizophrenia. NeuroImage 2009, 53: 1007-1015. PMID: 19944766, PMCID: PMC3968678, DOI: 10.1016/j.neuroimage.2009.11.052.Peer-Reviewed Original ResearchMeSH KeywordsAcoustic StimulationBrain MappingBrain-Derived Neurotrophic FactorDopamine Plasma Membrane Transport ProteinsEndophenotypesFemaleGenetic Predisposition to DiseaseGenotypeHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleNeural PathwaysPilot ProjectsPolymorphism, Single NucleotideSchizophreniaSerotonin Plasma Membrane Transport ProteinsConceptsDopamine transporterBrain functionNeurotropic factorAuditory oddball taskSchizophrenia patientsSingle nucleotide polymorphismsMultiple risk genesRisk genesOddball taskRelated brain functionsHealthy controlsSchizophrenia risk genesAbnormal activationGenomic factorsTemporal gyrusPatientsTask-relevant regionsSchizophreniaSignificant differencesAttention/Multiple single nucleotide polymorphismsGenetic profilePsychiatric neuroimagingBrainGenotype-phenotype relationships
2007
The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk
Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Molecular Psychiatry 2007, 13: 531-543. PMID: 17622222, PMCID: PMC3163084, DOI: 10.1038/sj.mp.4002035.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismCase-Control StudiesCocaine-Related DisordersEuropeExonsFemaleGenetic Predisposition to DiseaseHaplotypesHeroin DependenceHumansLinkage DisequilibriumMaleMiddle AgedPolymorphism, Single NucleotideReceptors, Opioid, deltaReceptors, Opioid, kappaRiskSubstance-Related DisordersUnited StatesConceptsLogistic regression analysisSingle nucleotide polymorphismsRegression analysisTag single nucleotide polymorphismsOPRD1 variantsG alleleC alleleDrug dependenceSignificant associationRisk effectsEuropean AmericansStratification artifactSignificant differencesPositive associationHaplotypic associationsMultiple testingAssociationOPRK1OPRD1Dependence riskSD
2001
Case control and family‐based studies of tryptophan hydroxylase gene A218C polymorphism and suicidality in adolescents
Zalsman G, Frisch A, King R, Pauls D, Grice D, Gelernter J, Alsobrook J, Michaelovsky E, Apter A, Tyano S, Weizman A, Leckman J. Case control and family‐based studies of tryptophan hydroxylase gene A218C polymorphism and suicidality in adolescents. American Journal Of Medical Genetics 2001, 105: 451-457. PMID: 11449398, DOI: 10.1002/ajmg.1406.Peer-Reviewed Original ResearchConceptsSuicidal behaviorSuicide riskA218C polymorphismDetailed clinical historyHaplotype relative riskAssociation of suicidalityTransmission disequilibrium test (TDT) methodsTryptophan hydroxylase geneAdolescent suicidal behaviorClinical historySame ethnic populationRelative riskCase controlAA genotypeControl groupFamily-based studySuicide intentSignificant allelic associationSignificant differencesEthnic populationsStructured interviewsInpatient adolescentsRiskAssociationSuicidalityFamily‐based association study of serotonin transporter promoter in suicidal adolescents: No association with suicidality but possible role in violence traits
Zalsman G, Frisch A, Bromberg M, Gelernter J, Michaelovsky E, Campino A, Erlich Z, Tyano S, Apter A, Weizman A. Family‐based association study of serotonin transporter promoter in suicidal adolescents: No association with suicidality but possible role in violence traits. American Journal Of Medical Genetics 2001, 105: 239-245. PMID: 11353442, DOI: 10.1002/ajmg.1261.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnalysis of VarianceCarrier ProteinsFamily HealthFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansIsraelMaleMembrane GlycoproteinsMembrane Transport ProteinsMental DisordersNerve Tissue ProteinsPhenotypePolymorphism, GeneticPromoter Regions, GeneticPsychology, AdolescentSerotonin Plasma Membrane Transport ProteinsSuicide, AttemptedViolenceConceptsSuicidal behaviorDetailed clinical historySerotonin transporter promoterSuicide-related behaviorsPromoter region polymorphismsSerotonin dysfunctionClinical parametersClinical historyBlood samplesHaplotype relative risk methodRelative risk methodSuicidal adolescentsSuicide riskLS genotypeAdolescent inpatientsAnxiety disordersSuicide intentSignificant allelic associationSuicidal adolescent inpatientsSignificant differencesFamily-based association studyPatientsRegion polymorphismsTransporter promoterPossible role
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity
1989
Corpus callosum dimensions measured by magnetic resonance imaging in bipolar affective disorder and schizophrenia
Hauser P, Dauphinais I, Berrettini W, DeLisi L, Gelernter J, Post R. Corpus callosum dimensions measured by magnetic resonance imaging in bipolar affective disorder and schizophrenia. Biological Psychiatry 1989, 26: 659-668. PMID: 2804188, DOI: 10.1016/0006-3223(89)90100-5.Peer-Reviewed Original ResearchConceptsCerebral areasMagnetic resonance imaging (MRI) brain scansBipolar affective patientsNormal control subjectsBipolar affective disorderControl subjectsCallosal areaPsychiatric illnessCallosal regionsSchizophrenic patientsAffective patientsGender differencesAffective disordersControl groupBrain scansMale subjectsDiagnostic groupsSchizophrenic groupFemale subjectsTesla scannerMidsagittal sliceSignificant differencesPatientsCallosalGenu